hr status in determining the efficacy of platinum therapy in advanced tnbc
Published 1 year ago • 105 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
1:14
the importance of a biomarker-directed approach in triple-negative breast cancer
-
1:22
dora: durvalumab and olaparib in platinum treated advanced tnbc
-
2:05
treatment advances in tnbc
-
1:26
the association of the her2dx signatures with survival in tnbc
-
0:41
recent advances in targeted therapies for tnbc
-
2:09
triplet combination of chemotherapy, cd40 agonist, and flt3 ligand in triple-negative breast cancer
-
2:07
the association between jnk activity and immunotherapeutic efficacy of io in tnbc
-
2:38
olaparib durvalumab as a chemotherapy-free maintenance strategy in platinum treated advanced tnbc
-
1:51
optimal chemotherapy combinations in tnbc gbrca subtypes
-
1:15
clinical implications of progress in tnbc therapies
-
0:51
challenges in the treatment of mtnbc
-
1:58
targeted therapy in tnbc
-
2:46
de-escalation of therapy in early-stage tnbc
-
1:22
immunological signatures to predict outcomes in patients with tnbc
-
1:30
begonia: durvalumab combinations in advanced tnbc
-
0:42
can anthracyclines be omitted in tnbc?
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
4:38
alice: atezolizumab immunogenic chemotherapy in metastatic tnbc
-
1:59
effectiveness of icis in the neoadjuvant and post-neoadjuvant breast cancer setting